Annual Cash & Cash Equivalents
$61.74 M
-$145.60 M-70.22%
31 December 2023
Summary:
Pharming Group NV annual cash & cash equivalents is currently $61.74 million, with the most recent change of -$145.60 million (-70.22%) on 31 December 2023. During the last 3 years, it has fallen by -$143.42 million (-69.91%). PHAR annual cash & cash equivalents is now -70.22% below its all-time high of $207.34 million, reached on 31 December 2022.PHAR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$60.66 M
+$13.52 M+28.68%
30 September 2024
Summary:
Pharming Group NV quarterly cash and cash equivalents is currently $60.66 million, with the most recent change of +$13.52 million (+28.68%) on 30 September 2024. Over the past year, it has increased by +$6.01 million (+10.99%). PHAR quarterly cash and cash equivalents is now -70.74% below its all-time high of $207.34 million, reached on 31 December 2022.PHAR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PHAR Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -70.2% | +11.0% |
| 3 y3 years | -69.9% | -66.9% |
| 5 y5 years | -32.8% | -11.9% |
PHAR Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -70.2% | at low | -70.7% | +28.7% |
| 5 y | 5 years | -70.2% | at low | -70.7% | +28.7% |
| alltime | all time | -70.2% | +1161.2% | -70.7% | +3116.1% |
Pharming Group NV Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $60.66 M(+28.7%) |
| June 2024 | - | $47.14 M(-9.2%) |
| Mar 2024 | - | $51.89 M(-16.0%) |
| Dec 2023 | $61.74 M(-70.2%) | $61.74 M(+13.0%) |
| Sept 2023 | - | $54.65 M(-71.6%) |
| June 2023 | - | $192.37 M(+4.1%) |
| Mar 2023 | - | $184.78 M(-10.9%) |
| Dec 2022 | $207.34 M(+8.0%) | $207.34 M(+9.9%) |
| Sept 2022 | - | $188.70 M(-0.7%) |
| June 2022 | - | $189.96 M(+0.2%) |
| Mar 2022 | - | $189.67 M(-1.2%) |
| Dec 2021 | $191.92 M(-6.5%) | $191.92 M(+4.7%) |
| Sept 2021 | - | $183.31 M(-2.7%) |
| June 2021 | - | $188.39 M(-8.7%) |
| Mar 2021 | - | $206.25 M(+0.5%) |
| Dec 2020 | $205.16 M(+175.9%) | $205.16 M(+12.9%) |
| Sept 2020 | - | $181.74 M(+5.8%) |
| June 2020 | - | $171.83 M(+16.4%) |
| Mar 2020 | - | $147.61 M(+98.5%) |
| Dec 2019 | $74.35 M(-19.1%) | $74.35 M(+7.9%) |
| Sept 2019 | - | $68.89 M(-5.2%) |
| June 2019 | - | $72.64 M(-0.9%) |
| Mar 2019 | - | $73.29 M(-20.2%) |
| Dec 2018 | $91.87 M(+30.5%) | $91.87 M(+11.3%) |
| Sept 2018 | - | $82.53 M(+8.9%) |
| June 2018 | - | $75.78 M(+5.1%) |
| Mar 2018 | - | $72.07 M(+2.4%) |
| Dec 2017 | $70.37 M(+109.8%) | $70.37 M(+56.1%) |
| Sept 2017 | - | $45.08 M(+57.6%) |
| June 2017 | - | $28.60 M(-2.2%) |
| Mar 2017 | - | $29.24 M(-12.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $33.54 M(-3.1%) | $33.54 M(+78.3%) |
| Sept 2016 | - | $18.81 M(-21.0%) |
| June 2016 | - | $23.82 M(-23.6%) |
| Mar 2016 | - | $31.17 M(-9.9%) |
| Dec 2015 | $34.60 M(-16.8%) | $34.60 M(-11.8%) |
| Sept 2015 | - | $39.22 M(+41.1%) |
| June 2015 | - | $27.79 M(-14.8%) |
| Mar 2015 | - | $32.62 M(-21.5%) |
| Dec 2014 | $41.57 M(+77.4%) | $41.57 M(+38.6%) |
| Sept 2014 | - | $29.99 M(-16.3%) |
| June 2014 | - | $35.82 M(+40.0%) |
| Mar 2014 | - | $25.58 M(+9.2%) |
| Dec 2013 | $23.43 M(+236.0%) | $23.43 M(+36.7%) |
| Sept 2013 | - | $17.14 M(+1.0%) |
| June 2013 | - | $16.98 M(-26.8%) |
| Mar 2013 | - | $23.18 M(+232.4%) |
| Dec 2012 | $6.97 M(+42.5%) | $6.97 M(+269.7%) |
| Sept 2012 | - | $1.89 M(-82.1%) |
| Mar 2012 | - | $10.53 M(+115.2%) |
| Dec 2011 | $4.90 M(-64.3%) | $4.90 M(-58.7%) |
| Sept 2011 | - | $11.86 M(-17.3%) |
| June 2011 | - | $14.34 M(-29.9%) |
| Mar 2011 | - | $20.45 M(+49.3%) |
| Dec 2010 | $13.70 M(-39.9%) | $13.70 M(-40.2%) |
| Sept 2010 | - | $22.90 M(-42.2%) |
| June 2010 | - | $39.64 M(+38.5%) |
| Mar 2010 | - | $28.61 M(+25.4%) |
| Dec 2009 | $22.81 M(-50.7%) | $22.81 M |
| Dec 2008 | $46.29 M(-48.1%) | - |
| Dec 2007 | $89.13 M(+158.9%) | - |
| Dec 2006 | $34.42 M(+101.1%) | - |
| Dec 2005 | $17.12 M | - |
FAQ
- What is Pharming Group NV annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pharming Group NV?
- What is Pharming Group NV annual cash & cash equivalents year-on-year change?
- What is Pharming Group NV quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Pharming Group NV?
- What is Pharming Group NV quarterly cash and cash equivalents year-on-year change?
What is Pharming Group NV annual cash & cash equivalents?
The current annual cash & cash equivalents of PHAR is $61.74 M
What is the all time high annual cash & cash equivalents for Pharming Group NV?
Pharming Group NV all-time high annual cash & cash equivalents is $207.34 M
What is Pharming Group NV annual cash & cash equivalents year-on-year change?
Over the past year, PHAR annual cash & cash equivalents has changed by -$145.60 M (-70.22%)
What is Pharming Group NV quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PHAR is $60.66 M
What is the all time high quarterly cash and cash equivalents for Pharming Group NV?
Pharming Group NV all-time high quarterly cash and cash equivalents is $207.34 M
What is Pharming Group NV quarterly cash and cash equivalents year-on-year change?
Over the past year, PHAR quarterly cash and cash equivalents has changed by +$6.01 M (+10.99%)